What we invest in

AI MEETS BIOLOGY

Based on the patient first approach, we are seeing the convergence of patient data, wet lab biology, and AI algorithms. This allows for a holistic and robust approach to patient profiling and understanding disease complexity and heterogeneity for more sensitive diagnostics and targeted therapies.

PLATFORM TECHNOLOGIES

Ranging from drug delivery to gene editing technologies, platform technologies could be used across multiple assets or to develop assets applicable across multiple indications.

ENABLING TECHNOLOGIES

Increased use of customisable automation and analytical tools are enabling real-time precision measurements and control, leading to improved R&D for discovery, testing, and development/scale up of new drugs and materials faster.

750K-1.5mio EUR

Initial ticket size

(Pre-) Seed & Series A

Stages

Europe

Geography

Portfolio entrepreneurs about techbio

OUR TECHBIO PORTFOLIO

Nothing found.

Nothing found.

WITH US, YOU CAN CO-INVEST WITH THEM

Verve's investor network

We’re not alone in our mission. We co-invest with some of the most sophisticated venture capital firms focusing on industrial change. And our network of qualified private investors can co-invest with us alongside these firms. If you want to contribute to solving the challenges of human health with your techbio investments, you should join us.

Frequently Asked Questions

With over 10 years of experience and 30+ investments under the healthcare umbrella, and driven by the large network of LPs and portfolio founders, we are one of the few European investors with the technical, commercial, and operational expertise in growing the companies, and supporting on market entry, expansion, technical scalability, biopharma partnerships, and fundraising.

While we do not invest in single asset or single indication therapeutics, we have invested and will continue to invest in platform technologies that allow for development of multiple assets applicable across multiple indications or allow for licensing of the technology for co-developing assets with biopharma.

Yes! We have a mix of hardware and software only companies in our portfolio. However, we believe in owning the entire value chain and that real differentiation comes from building at the intersection of multiple disciplines.

With over 10 years of experience in high tech investments and technical founding teams, we understand the specific challenges and opportunities of scaling such startups. We have built an extensive network of advisors, co-investors, partners and potential clients that is at your disposal.

As DeepTech investors we understand the timelines in TechBio and are able to provide capital for the long run. We focus on long-term company building and value generation rather than short-term optimization.

Yes, you could find us in local techbio events in the EU and the UK, and the large healthcare conferences (e.g., JPM, LSX). However, you do not need to wait for an in person meeting. You are welcome to reach out to Perman with a brief summary about yourself and your company.

The right timing for a funding round can vary depending on your specific business. Generally, being able to show an MVP or even a full product, first market traction through LOIs or POCs, as well as a well-functioning core team and ideally product market fit are decisive factors.

We’d like to get to know you and your team early on. Therefore, we are also happy to start an initial conversation without first market traction or if you are not fundraising at the moment. We suggest reaching out to the one of the TechBio team members above.